New and recently funded Medical Startups
1
Country: USA | Funding: $20M
Blossom Health is a telehealth platform that specializes in psychiatry, aiming to provide access to mental health services.
Blossom Health is a telehealth platform that specializes in psychiatry, aiming to provide access to mental health services.
2
Country: USA | Funding: $200M
eMed focuses on employer-sponsored preemptive health management, providing personalized solutions for workforce health.
eMed focuses on employer-sponsored preemptive health management, providing personalized solutions for workforce health.
3
Country: USA | Funding: $25M
Jimini Health develops AI-assisted solutions for behavioral health care, focusing on continuous patient support between clinical sessions.
Jimini Health develops AI-assisted solutions for behavioral health care, focusing on continuous patient support between clinical sessions.
4
Country: USA | Funding: $6.4M
Acurion develops AI-powered oncology precision medicine platform OncoGaze that analyzes genomic biomarkers from routine clinical slides to help clinicians select personalized therapies. The company says OncoGaze can detect genomic biomarkers from routine clinical slides for every cancer, allowing for real-time therapy selection.
Acurion develops AI-powered oncology precision medicine platform OncoGaze that analyzes genomic biomarkers from routine clinical slides to help clinicians select personalized therapies. The company says OncoGaze can detect genomic biomarkers from routine clinical slides for every cancer, allowing for real-time therapy selection.
5
Country: China | Funding: $418.5M
OriCell Therapeutics aims to develop drugs with good efficacy and affordable prices for tumor immunotherapy. The company’s pipeline is headed up by Ori-C101, a GPC3-targeted autologous CAR-T therapy against hepatocellular carcinoma (HCC). The biotech is now gearing up for further studies with the ultimate aim of making Ori-C101 the first globally-approved CAR-T for HCC.
OriCell Therapeutics aims to develop drugs with good efficacy and affordable prices for tumor immunotherapy. The company’s pipeline is headed up by Ori-C101, a GPC3-targeted autologous CAR-T therapy against hepatocellular carcinoma (HCC). The biotech is now gearing up for further studies with the ultimate aim of making Ori-C101 the first globally-approved CAR-T for HCC.
6
Country: USA | Funding: $358M
Terremoto Biosciences is a biotechnology company leveraging the power of lysine-based covalency to develop optimized medicines. The lead candidate in this pipeline, dubbed TER-2013 - AKT1-selective inhibitor, is already in the clinic as a potential treatment for solid tumors with PIK3CA, AKT or PTEN mutations.
Terremoto Biosciences is a biotechnology company leveraging the power of lysine-based covalency to develop optimized medicines. The lead candidate in this pipeline, dubbed TER-2013 - AKT1-selective inhibitor, is already in the clinic as a potential treatment for solid tumors with PIK3CA, AKT or PTEN mutations.
7
Country: UK | Funding: $125.6M
Storm Therapeutics develops small-molecule therapies that target RNA-modifying enzymes to treat cancer and other diseases. The company conducts a trial of its RNA-modifying enzyme inhibitor against sarcoma.
Storm Therapeutics develops small-molecule therapies that target RNA-modifying enzymes to treat cancer and other diseases. The company conducts a trial of its RNA-modifying enzyme inhibitor against sarcoma.
8
Country: USA | Funding: $106M
Tortugas Neuroscience is developing a pipeline of TRTL-107, a D2/D3 partial agonist and 5-HT2A antagonist licensed from China’s Hansoh, and is being evaluated for schizophrenia. The other drug licensed from Hansoh is a GABA receptor-positive allosteric modulator aimed at treating tinnitus.
Tortugas Neuroscience is developing a pipeline of TRTL-107, a D2/D3 partial agonist and 5-HT2A antagonist licensed from China’s Hansoh, and is being evaluated for schizophrenia. The other drug licensed from Hansoh is a GABA receptor-positive allosteric modulator aimed at treating tinnitus.
9
Country: USA | Funding: $247M
Ray Therapeutics is a biotech company that develops optogenetic gene therapies for patients with blinding diseases.
Ray Therapeutics is a biotech company that develops optogenetic gene therapies for patients with blinding diseases.
10
Country: USA | Funding: $50M
Serif Biomedicines uses circular DNA with certain chemical modifications to solve several problems that plague traditional gene therapy. Namely, the class of medicines provokes an immune response and is difficult to manufacture. Serif’s approach is to instead use modified DNA that is packaged inside of lipid nanoparticles. This DNA is accompanied by mRNA that, once inside the cell, is turned into proteins that shuttle the DNA into the nucleus, where it can itself be turned into a therapeutic protein.
Serif Biomedicines uses circular DNA with certain chemical modifications to solve several problems that plague traditional gene therapy. Namely, the class of medicines provokes an immune response and is difficult to manufacture. Serif’s approach is to instead use modified DNA that is packaged inside of lipid nanoparticles. This DNA is accompanied by mRNA that, once inside the cell, is turned into proteins that shuttle the DNA into the nucleus, where it can itself be turned into a therapeutic protein.
